SIGA Technologies Inc. (SIGA): Price and Financial Metrics

SIGA Technologies Inc. (SIGA): $9.15

-1.68 (-15.51%)

POWR Rating

Component Grades













Add SIGA to Watchlist
Sign Up

Industry: Biotech



in industry


  • SIGA scores best on the Quality dimension, with a Quality rank ahead of 98.94% of US stocks.
  • The strongest trend for SIGA is in Growth, which has been heading up over the past 179 days.
  • SIGA's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

SIGA Stock Summary

  • The price/operating cash flow metric for Siga Technologies Inc is higher than 88.35% of stocks in our set with a positive cash flow.
  • For SIGA, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • SIGA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 12.76% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Siga Technologies Inc are FLUX, CYBE, TELL, SPNS, and CSGS.
  • Visit SIGA's SEC page to see the company's official filings. To visit the company's web site, go to

SIGA Valuation Summary

  • In comparison to the median Healthcare stock, SIGA's price/sales ratio is 34.21% higher, now standing at 5.1.
  • SIGA's price/earnings ratio has moved up 18.7 over the prior 221 months.
  • Over the past 221 months, SIGA's price/sales ratio has gone down 38.2.

Below are key valuation metrics over time for SIGA.

Stock Date P/S P/B P/E EV/EBIT
SIGA 2021-08-31 5.1 4.2 11.2 6.8
SIGA 2021-08-30 5.1 4.2 11.2 6.8
SIGA 2021-08-27 5.0 4.1 11.0 6.7
SIGA 2021-08-26 5.0 4.1 10.9 6.6
SIGA 2021-08-25 5.0 4.1 11.0 6.6
SIGA 2021-08-24 5.1 4.2 11.1 6.8

SIGA Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at 58.43%.
  • Its year over year net cashflow from operations growth rate is now at 525.69%.
  • Its 5 year net income to common stockholders growth rate is now at 58.43%.
Over the past 70 months, SIGA's revenue has gone up $125,416,935.

The table below shows SIGA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 133.6705 11.49464 69.45077
2021-09-30 56.04256 41.33845 16.40516
2021-06-30 95.4578 71.04887 43.70648
2021-03-31 127.1533 63.39047 64.42744
2020-12-31 124.9593 71.51923 56.34201
2020-09-30 91.49402 11.30855 31.67798

SIGA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SIGA has a Quality Grade of A, ranking ahead of 98.42% of graded US stocks.
  • SIGA's asset turnover comes in at 0.402 -- ranking 116th of 682 Pharmaceutical Products stocks.
  • INFI, TTNP, and PALI are the stocks whose asset turnover ratios are most correlated with SIGA.

The table below shows SIGA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.402 0.899 0.927
2021-06-30 0.677 0.883 1.972
2021-03-31 0.924 0.883 2.388
2020-12-31 0.943 0.882 2.253
2020-09-30 0.632 0.884 1.360
2020-06-30 0.346 0.896 0.269

SIGA Stock Price Chart Interactive Chart >

Price chart for SIGA

SIGA Price/Volume Stats

Current price $9.15 52-week high $14.80
Prev. close $10.83 52-week low $5.66
Day low $8.47 Volume 25,981,042
Day high $10.48 Avg. volume 2,386,006
50-day MA $7.38 Dividend yield N/A
200-day MA $7.12 Market Cap 662.52M

SIGA Technologies Inc. (SIGA) Company Bio

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.

SIGA Latest News Stream

Event/Time News Detail
Loading, please wait...

SIGA Latest Social Stream

Loading social stream, please wait...

View Full SIGA Social Stream

Latest SIGA News From Around the Web

Below are the latest news stories about Siga Technologies Inc that investors may wish to consider to help them evaluate SIGA as an investment opportunity.

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

Investigating TPOXX® in Combination with Bioarchitech’s Oncolytic Vaccinia Immunotherapy PlatformNEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Bioarchitech, a United Kingdom-based biotech company developing immunotherapy for the treatment of cancer. The research collaboration will investigate TPOXX® (tecovirimat) i

Yahoo | January 25, 2022

SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group’s Open House Event, scheduled to take place virtually this month. SIGA Chief Executive Officer, Phil Gomez, will be presenting and will be available for 1x1 meetings. For more information on the event and details on how to register, please see below. Event: Edison G

Yahoo | January 18, 2022

SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency (EMA) approved SIGA''s Marketing Authorisation Application (MAA) for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration (FDA) in July 2018 under the brand name TPOXX ® . The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The MAA was filed under the centralized application process, which, upon approval, enables sales, including procurement for stockpiling, of oral tecovirimat in all ...

Benzinga | January 10, 2022

Those who invested in SIGA Technologies (NASDAQ:SIGA) five years ago are up 154%

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Yahoo | January 6, 2022

SIGA Technologies (NASDAQ:SIGA) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of SIGA Technologies (NASDAQ:SIGA) from a hold rating to a buy rating in a report published on Wednesday morning, reports. The brokerage currently has $8.50 price objective on the stock. According to Zacks, SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design []

Transcript Daily | December 23, 2021

Read More 'SIGA' Stories Here

SIGA Price Returns

1-mo 33.58%
3-mo 52.75%
6-mo N/A
1-year 31.47%
3-year 58.58%
5-year 165.22%
YTD 21.68%
2021 3.44%
2020 52.41%
2019 -39.62%
2018 62.89%
2017 68.40%

Continue Researching SIGA

Here are a few links from around the web to help you further your research on Siga Technologies Inc's stock as an investment opportunity:

Siga Technologies Inc (SIGA) Stock Price | Nasdaq
Siga Technologies Inc (SIGA) Stock Quote, History and News - Yahoo Finance
Siga Technologies Inc (SIGA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4783 seconds.